aledopress

A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis

Nov 18, 2020 aledopress

Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.. ..In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to… Continue reading A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis

#Dementia and the risk of death in elderly patients with #COVID‐19 infection: Systematic review and meta‐analysis

Nov 18, 2020 aledopress

The COVID‐19 infection represents a global public health emergency worldwide. Several risk factors have been associated with a poor prognosis among COVID‐19 patients. We aimed to perform a systemic review and meta‐analysis to evaluate the mortality risk in elderly patients with dementia and COVID‐19 infection.. ..A total of 233 articles were retrieved; 158 were excluded… Continue reading #Dementia and the risk of death in elderly patients with #COVID‐19 infection: Systematic review and meta‐analysis

Polypill with or without Aspirin in Persons without #Cardiovascular Disease

Nov 17, 2020 aledopress

..Using a 2-by-2-by-2 factorial design, we randomly assigned participants without cardiovascular disease who had an elevated INTERHEART Risk Score to receive a polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily, aspirin (75 mg) or placebo daily, and vitamin D or placebo… Continue reading Polypill with or without Aspirin in Persons without #Cardiovascular Disease

Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of #Heart Failure and Myocardial #Infarction in Type 2 #Diabetes: Findings From the Look AHEAD Trial

Nov 17, 2020Nov 14, 2020 aledopress

https://bit.ly/2Uqsd5F

Lower abdominal and pelvic radiation and #testicular germ cell tumor risk

Nov 16, 2020 aledopress

Testicular germ cell tumor (TGCT) incidence has increased in recent decades along with the use and dose of diagnostic radiation. Here we examine the association between reported exposure to diagnostic radiation and TGCT risk.. ..There were 315 men with TGCT and 931 men without TGCT in our study. Compared to no exposures, risk of TGCT… Continue reading Lower abdominal and pelvic radiation and #testicular germ cell tumor risk

Preexisting and de novo humoral immunity to #SARS-CoV-2 in humans

Nov 16, 2020 aledopress

Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detect preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable by a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the IgG class and… Continue reading Preexisting and de novo humoral immunity to #SARS-CoV-2 in humans

#Smoking Cessation, #Weight Change, #Diabetes, and #Hypertension in Korean Adult

Nov 15, 2020 aledopress

This study investigates the association of smoking cessation and postcessation weight gain with the development of type 2 diabetes mellitus and hypertension. Methods A total of 96,524 individuals without diabetes mellitus and hypertension aged ≥20 years between 2006 and 2008 were included, with follow-up until December 31, 2015. Smoking status and weight changes were monitored… Continue reading #Smoking Cessation, #Weight Change, #Diabetes, and #Hypertension in Korean Adult

Efficacy and Safety Over 2 Years of #Exenatide Plus #Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

Nov 15, 2020 aledopress

In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a… Continue reading Efficacy and Safety Over 2 Years of #Exenatide Plus #Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial